The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19

Wulyo Rajabto,1,2 Vitya Chandika,1 Agnes Stephanie Harahap,3 Maria Francisca Ham3 1Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/ Faculty of Medicine Universitas Indonesia, Central Jakarta, Indonesia; 2Department of Internal Medicin...

Full description

Bibliographic Details
Main Authors: Rajabto W, Chandika V, Harahap AS, Ham MF
Format: Article
Language:English
Published: Dove Medical Press 2022-06-01
Series:International Medical Case Reports Journal
Subjects:
brentuximab vedotin
covid-19
monotherapy
refractory hodgkin's lymphoma
Online Access:https://www.dovepress.com/the-role-of-brentuximab-vedotin-bv-as-second-line-treatment-of-refract-peer-reviewed-fulltext-article-IMCRJ

Internet

https://www.dovepress.com/the-role-of-brentuximab-vedotin-bv-as-second-line-treatment-of-refract-peer-reviewed-fulltext-article-IMCRJ

Similar Items